Literature DB >> 27599516

Dependence of anxiolytic effects of the dipeptide TSPO ligand GD-23 on neurosteroid biosynthesis.

T A Gudasheva1, O A Deeva2, M A Yarkova2, S B Seredenin2.   

Abstract

The elevated plus maze test showed that GD-23 (N-carbobenzoxy-L-tryptophanyl-L-isoleucine amide), an original dipeptide ligand of TSPO, exerted anxiolytic effect when injected intraperitoneally at a dose of 0.5 mg/kg. This effect was completely blocked by the selective neurosteroid synthesis inhibitors, enzymes trilostane and finasteride. The same inhibitors do not prevent the anxiolytic effects of the benzodiazepine tranquillizer diazepam. The results of the study indicate the selective neurosteroidogenic mechanism of the anxiolytic action of GD-23.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27599516     DOI: 10.1134/S1607672916040165

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  12 in total

Review 1.  Neurosteroids: biochemistry and clinical significance.

Authors:  Synthia H Mellon; Lisa D Griffin
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

2.  The first dipeptide ligand of translocator protein: Design and anxiolytic activity.

Authors:  T A Gudasheva; O A Deeva; G V Mokrov; S A Yarkov; M A Yarkova; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2015-10-31       Impact factor: 0.788

Review 3.  Factors controlling measures of anxiety and responses to novelty in the mouse.

Authors:  S E File
Journal:  Behav Brain Res       Date:  2001-11-01       Impact factor: 3.332

4.  2-Phenyl-imidazo[1,2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats.

Authors:  M Serra; P Madau; M F Chessa; M Caddeo; E Sanna; G Trapani; M Franco; G Liso; R H Purdy; M L Barbaccia; G Biggio
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 5.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 6.  Development of ligands for the peripheral benzodiazepine receptor.

Authors:  Michelle L James; Silvia Selleri; Michael Kassiou
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 7.  The role of allopregnanolone in depression and anxiety.

Authors:  Cornelius Schüle; Caroline Nothdurfter; Rainer Rupprecht
Journal:  Prog Neurobiol       Date:  2013-11-08       Impact factor: 11.685

8.  Design, synthesis and structure-activity relationship of novel tricyclic benzimidazolone derivatives as potent 18 kDa translocator protein (TSPO) ligands.

Authors:  Takayuki Fukaya; Toru Kodo; Takeo Ishiyama; Hiroyuki Nishikawa; Satoko Baba; Shuji Masumoto
Journal:  Bioorg Med Chem       Date:  2012-12-27       Impact factor: 3.641

Review 9.  Neurosteroids, stress and depression: potential therapeutic opportunities.

Authors:  Charles F Zorumski; Steven M Paul; Yukitoshi Izumi; Douglas F Covey; Steven Mennerick
Journal:  Neurosci Biobehav Rev       Date:  2012-10-17       Impact factor: 8.989

Review 10.  Neurosteroid binding sites on GABA(A) receptors.

Authors:  Alastair M Hosie; Megan E Wilkins; Trevor G Smart
Journal:  Pharmacol Ther       Date:  2007-04-21       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.